Inhibition of TGF-β signaling in bone marrow endothelial cells promotes hematopoietic recovery in acute myeloid leukemia patients
Cancer Letters · 2024
DOI: 10.1016/j.canlet.2024.217290 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2024. Verfasst von Zhen-Kun Wang und 16 weiteren Autor:innen. Beteiligte Einrichtung: Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Ke…. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Signal Transduction, Endothelial Cells, Hematopoiesis. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 65 Literaturangaben. Gefördert von: Natural Science Foundation of Beijing Municipality, Peking University, National Natural Science Foundation of China.
Abstract (Originalsprache)
Although it is an effective treatment for acute myeloid leukemia (AML), chemotherapy leads to myelosuppression and poor hematopoietic reconstruction. Hematopoiesis is regulated by bone marrow (BM) endothelial cells (ECs), and BM ECs are dysfunctional in acute leukemia patients with poor hematopoietic reconstitution after allogenic hematopoietic stem cell transplantation. Thus, it is crucial to explore the underlying mechanism of EC impairment and establish strategies for targeted therapy. TGF-β signaling was found to be upregulated in ECs from AML patients in complete remission (CR ECs) and led to CR EC damage. Administration of a TGF-β inhibitor rescued the dysfunction of ECs caused by TGF-β1 expression in vitro, especially their hematopoiesis-supporting ability. Moreover, inhibition of TGF-β expression repaired the BM EC damage triggered by chemotherapy in both AML patients in vitro and in an AML-CR murine model, and restored normal hematopoiesis without promoting AML progression. Mechanistically, our data reveal alterations in the transcriptomic pattern of damaged BM ECs, accompanied by the overexpression of downstream molecules TGF-βR1, pSmad2/3, and functional genes related to adhesion, angiogenesis suppression and pro-apoptosis. Collectively, our findings reveal for the first time that the activation of TGF-β signaling leads to BM EC dysfunction and poor hematopoietic reconstitution. Targeting TGF-β represents a potential therapeutic strategy to promote multilineage hematopoiesis, thereby benefiting more cancer patients who suffer from myelosuppression after chemotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Collaborative…
Förderung
- Natural Science Foundation of Beijing Municipality
- Peking University
- National Natural Science Foundation of China
- National Key Research and Development Program of China
Zitieren
APA
Wang, Z. K., Zhang, Z. W., Lyu, Z. S., Xing, T., Liang, M., Shen, M. Z., Li, C. Y., Zhang, X. Y., Chen, D. D., Wang, Y. Z., Hu, L. J., Jiang, H., Wang, Y., Jiang, Q., Zhang, X. H., Kong, Y., & Huang, X. J. (2024). Inhibition of TGF-β signaling in bone marrow endothelial cells promotes hematopoietic recovery in acute myeloid leukemia patients. Cancer Letters. https://doi.org/10.1016/j.canlet.2024.217290
Vancouver
Wang ZK, Zhang ZW, Lyu ZS, Xing T, Liang M, Shen MZ, et al. Inhibition of TGF-β signaling in bone marrow endothelial cells promotes hematopoietic recovery in acute myeloid leukemia patients. Cancer Letters. 2024. doi:10.1016/j.canlet.2024.217290
BibTeX
@article{Wang2024,
author = {Wang, Zhen-Kun and Zhang, Zhi-Wei and Lyu, Zhong-Shi and Xing, Tong and Liang, Mi and Shen, Meng-Zhu and Li, Chen-Yuan and Zhang, Xin-Yan and Chen, Dan-Dan and Wang, Ya-Zhe and Hu, Li-Juan and Jiang, Hao and Wang, Yu and Jiang, Qian and Zhang, Xiao-Hui and Kong, Yuan and Huang, Xiao-Jun},
title = {Inhibition of TGF-β signaling in bone marrow endothelial cells promotes hematopoietic recovery in acute myeloid leukemia patients},
journal = {Cancer Letters},
year = {2024},
doi = {10.1016/j.canlet.2024.217290}
}
EUVIMED